T-helper (Th)1/Th2 imbalance in patients with previously untreated B-cell diffuse large cell lymphoma

被引:48
|
作者
Mori, T [1 ]
Takada, R [1 ]
Watanabe, R [1 ]
Okamoto, S [1 ]
Ikeda, Y [1 ]
机构
[1] Keio Univ, Sch Med, Dept Med, Div Hematol,Shinjuku Ku, Tokyo 1608582, Japan
关键词
Th1/Th2; balance; diffuse large cell lymphoma; non-Hodgkin's lymphoma;
D O I
10.1007/s00262-001-0232-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
T-helper (Th)1/Th2 imbalance has been observed in a variety of pathological conditions, including malignant diseases. We evaluated the Th1/Th2 balance in peripheral blood Th cells by means of intracellular cytokine analysis in 19 patients with previously untreated B-cell diffuse large cell lymphoma (DLCL) and in 18 patients with B-cell DLCL who had achieved complete remission (CR) after chemotherapy. The mean percentage of Th2 in CD4(+) cells in patients with DLCL (5.00 +/- 2.20) and that of Th1 in CD4(+) cells in patients in CR (32.42 +/- 11.30) were significantly increased in comparison with those in healthy volunteers, respectively (Th1; 23.02 +/- 9.45, Th2; 3.25 +/- 0.90; P < 0.01). The mean ratio of Th1/Th2 was significantly lower in patients with DLCL (4.74 +/- 0.52) than in patients in CR (9.31 +/- 1.06; P < 0.01) and in healthy volunteers (7.25 +/- 0.65; P < 0.01). We conclude that the Th1/Th2 balance was polarized to Th2 in untreated DLCL patients and to Th1 in patients in CR, which suggests that a Th1/Th2 imbalance could play a role in lymphomagenesis and durable remission.
引用
收藏
页码:566 / 568
页数:3
相关论文
共 50 条
  • [41] Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era
    Lehners, Nicola
    Kraemer, Isabelle
    Schwarzbich, Mark-Alexander
    Ho, Anthony D.
    Witzens-Harig, Mathias
    LEUKEMIA & LYMPHOMA, 2016, 57 (11) : 2619 - 2625
  • [42] REGULATION BY NORMAL T-HELPER CELLS OF B-CELL LYMPHOMA CELL-CYCLE PROGRESSION
    REID, SL
    SNOW, EC
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1995, : 176 - 176
  • [43] US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma
    Matasar, Matthew
    Masaquel, Anthony
    S. Ho, Rodrigo
    Launonen, Aino
    Ng, Carmen D.
    Wang, Rongrong
    Fox, David
    Hossain, Farah
    Li, Jia
    Burke, John M.
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 1134 - 1144
  • [44] Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
    Vitolo, Umberto
    Trneny, Marek
    Belada, David
    Burke, John M.
    Carella, Angelo Michele
    Chua, Neil
    Abrisqueta, Pau
    Demeter, Judit
    Flinn, Ian
    Hong, Xiaonan
    Kim, Won Seog
    Pinto, Antonio
    Shi, Yuan-Kai
    Tatsumi, Yoichi
    Oestergaard, Mikkel Z.
    Wenger, Michael
    Fingerle-Rowson, Gunter
    Catalani, Olivier
    Nielsen, Tina
    Martelli, Maurizio
    Sehn, Laurie H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (31) : 3529 - +
  • [45] GENERATION OF B-CELL MEMORY AND AFFINITY MATURATION - INDUCTION WITH TH1 AND TH2 T-CELL CLONES
    RIZZO, LV
    DEKRUYFF, RH
    UMETSU, DT
    JOURNAL OF IMMUNOLOGY, 1992, 148 (12): : 3733 - 3739
  • [46] Diffuse large B-cell lymphoma
    Barraclough, Allison
    Hawkes, Eliza
    Sehn, Laurie H.
    Smith, Sonali M.
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (06)
  • [47] Diffuse Large B-Cell Lymphoma
    Sehn, Laurie H.
    Salles, Gilles
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09): : 842 - 858
  • [48] Diffuse large B-cell lymphoma
    Li, Shaoying
    Young, Ken H.
    Medeiros, L. Jeffrey
    PATHOLOGY, 2018, 50 (01) : 74 - 87
  • [49] Diffuse large B-cell lymphoma
    Hunt, Kristin E.
    Reichard, Kaaren K.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2008, 132 (01) : 118 - 124
  • [50] Diffuse large B-cell lymphoma
    Fuchs, David
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2019, 12 (01) : 7 - 11